These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30973968)

  • 21. Diagnosis and management of non-alcoholic fatty liver disease.
    Jennison E; Patel J; Scorletti E; Byrne CD
    Postgrad Med J; 2019 Jun; 95(1124):314-322. PubMed ID: 31085617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Non-alcoholic liver disease - diagnosis and treatment].
    Sarosiekjeznach-Steinhagen A; Ostrowska J; Czerwonogrodzka-Senczyna A; Boniecka I
    Pol Merkur Lekarski; 2017 Nov; 43(257):237-242. PubMed ID: 29231919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin targets brown adipose tissue in vivo and reduces oxygen consumption in vitro.
    Breining P; Jensen JB; Sundelin EI; Gormsen LC; Jakobsen S; Busk M; Rolighed L; Bross P; Fernandez-Guerra P; Markussen LK; Rasmussen NE; Hansen JB; Pedersen SB; Richelsen B; Jessen N
    Diabetes Obes Metab; 2018 Sep; 20(9):2264-2273. PubMed ID: 29752759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Metformin-Single Therapy on the Level of Inflammatory Markers in Serum of Non-Obese T2DM Patients with NAFLD.
    Mitrovic B; Gluvic Z; Macut D; Obradovic M; Sudar-Milovanovic E; Soskic S; Stajic D; Isenovic ER
    Endocr Metab Immune Disord Drug Targets; 2022; 22(1):117-124. PubMed ID: 33632113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.
    Cusi K; Sanyal AJ; Zhang S; Hartman ML; Bue-Valleskey JM; Hoogwerf BJ; Haupt A
    Diabetes Obes Metab; 2017 Nov; 19(11):1630-1634. PubMed ID: 28417532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
    Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
    Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lonicera japonica extract increases metformin distribution in the liver without change of systemic exposed metformin in rats.
    Han SY; Chae HS; You BH; Chin YW; Kim H; Choi HS; Choi YH
    J Ethnopharmacol; 2019 Jun; 238():111892. PubMed ID: 31004727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin in Combination with Malvidin Prevents Progression of Non-Alcoholic Fatty Liver Disease via Improving Lipid and Glucose Metabolisms, and Inhibiting Inflammation in Type 2 Diabetes Rats.
    Zou W; Zhang C; Gu X; Li X; Zhu H
    Drug Des Devel Ther; 2021; 15():2565-2576. PubMed ID: 34168429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-alcoholic steatohepatitis, but not simple steatosis, disturbs the functional homogeneity of the liver - a human galactose positron emission tomography study.
    Eriksen PL; Thomsen KL; Larsen LP; Grønbaek H; Vilstrup H; Sørensen M
    Aliment Pharmacol Ther; 2019 Jul; 50(1):84-92. PubMed ID: 31099410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial.
    Haukeland JW; Konopski Z; Eggesbø HB; von Volkmann HL; Raschpichler G; Bjøro K; Haaland T; Løberg EM; Birkeland K
    Scand J Gastroenterol; 2009; 44(7):853-60. PubMed ID: 19811343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [11C]-Labeled Metformin Distribution in the Liver and Small Intestine Using Dynamic Positron Emission Tomography in Mice Demonstrates Tissue-Specific Transporter Dependency.
    Jensen JB; Sundelin EI; Jakobsen S; Gormsen LC; Munk OL; Frøkiær J; Jessen N
    Diabetes; 2016 Jun; 65(6):1724-30. PubMed ID: 26993065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity.
    Barchetta I; Enhörning S; Cimini FA; Capoccia D; Chiappetta C; Di Cristofano C; Silecchia G; Leonetti F; Melander O; Cavallo MG
    BMC Med; 2019 Apr; 17(1):85. PubMed ID: 31035998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
    Tahara A; Takasu T
    Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin.
    Chen EC; Liang X; Yee SW; Geier EG; Stocker SL; Chen L; Giacomini KM
    Mol Pharmacol; 2015 Jul; 88(1):75-83. PubMed ID: 25920679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation.
    Abdelmoemen G; Khodeir SA; Zaki AN; Kassab M; Abou-Saif S; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2019; 19(2):185-188. PubMed ID: 30009716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.